Literature DB >> 11173632

Lipoxygenase in Human Tumor Cells.

Wolfgang Hagmann1.   

Abstract

Tumor cell proliferation and metastasis proceed via a network of interdependent molecular events with a vast array of molecular players and signal transduction mechanisms differing in various types of human tumors. In the sequence of events necessary for carcinogenesis, arachidonate metabolites have been documented to play a significant role at several steps. Arachidonate metabolism in human cells occurs via several enzymatic pathways, including enzymes such as cyclo-oxygenases and lipoxygenases. This review pays particular attention to one member of the lipoxygenase family of enzymes, namely 12-lipoxygenase, since an arachidonate metabolite generated via 12-lipoxygenase action, 12(S)-HETE, has been shown to elicit various prometastatic effects of tumor cells in vivo and in vitro. We focus especially on mechanisms of activation and modulation of 12-lipoxygenase expression in human tumor cells, since various tumor cells express 12-lipoxygenase or are responsive to metabolites derived from 12-lipoxygenase action, thus offering a potential for successful therapeutic intervention against such tumors.

Entities:  

Year:  1997        PMID: 11173632     DOI: 10.1007/bf02907800

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  55 in total

1.  Specific action of the lipoxygenase pathway in mediating angiotensin II-induced aldosterone synthesis in isolated adrenal glomerulosa cells.

Authors:  J L Nadler; R Natarajan; N Stern
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

Review 2.  Epidermal growth factor.

Authors:  G Carpenter; S Cohen
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

3.  Modulation of the epidermal growth factor mitogenic response by metabolites of linoleic and arachidonic acid in Syrian hamster embryo fibroblasts. Differential effects in tumor suppressor gene (+) and (-) phenotypes.

Authors:  W C Glasgow; C A Afshari; J C Barrett; T E Eling
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

4.  Requirement for epidermal growth factor receptor tyrosine kinase and for 12-lipoxygenase activity in the expression of 12-lipoxygenase in human epidermoid carcinoma cells.

Authors:  W Hagmann; S Borgers
Journal:  Biochem Pharmacol       Date:  1997-04-04       Impact factor: 5.858

5.  Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase.

Authors:  J M Balcarek; T W Theisen; M N Cook; A Varrichio; S M Hwang; M W Strohsacker; S T Crooke
Journal:  J Biol Chem       Date:  1988-09-25       Impact factor: 5.157

6.  Cloning of the cDNA for human 12-lipoxygenase.

Authors:  T Izumi; S Hoshiko; O Rådmark; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

7.  Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK).

Authors:  D G Tang; M Tarrien; P Dobrzynski; K V Honn
Journal:  J Cell Physiol       Date:  1995-11       Impact factor: 6.384

8.  12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha.

Authors:  B Liu; R J Maher; Y A Hannun; A T Porter; K V Honn
Journal:  J Natl Cancer Inst       Date:  1994-08-03       Impact factor: 13.506

9.  Functional expression and cellular localization of a mouse epidermal lipoxygenase.

Authors:  C D Funk; D S Keeney; E H Oliw; W E Boeglin; A R Brash
Journal:  J Biol Chem       Date:  1996-09-20       Impact factor: 5.157

10.  12-Lipoxygenase in Lewis lung carcinoma cells: molecular identity, intracellular distribution of activity and protein, and Ca(2+)-dependent translocation from cytosol to membranes.

Authors:  W Hagmann; X Gao; A Zacharek; L A Wojciechowski; K V Honn
Journal:  Prostaglandins       Date:  1995-01
View more
  3 in total

Review 1.  Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis.

Authors:  Shivaprasad H Venkatesha; Brian M Berman; Kamal D Moudgil
Journal:  Bioorg Med Chem       Date:  2010-10-31       Impact factor: 3.641

2.  "Combination-oriented molecular-targeting prevention" of cancer: a model involving the combination of TRAIL and a DR5 inducer.

Authors:  Tatsushi Yoshida; Mano Horinaka; Toshiyuki Sakai
Journal:  Environ Health Prev Med       Date:  2010-01-06       Impact factor: 3.674

3.  A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.

Authors:  Tara Baetz; Elizabeth Eisenhauer; Lillian Siu; Martha MacLean; Karen Doppler; Wendy Walsh; Bryn Fisher; Azhar Z Khan; Dinesh P de Alwis; A Weitzman; Leslie H Brail; Malcolm Moore
Journal:  Invest New Drugs       Date:  2006-12-05       Impact factor: 3.651

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.